论文部分内容阅读
目的探讨噻托溴铵吸入剂治疗慢性阻塞性肺疾病(COPD)合并呼吸衰竭的临床效果。方法 120例确诊为COPD患者随机分为实验组和对照组,每组60例。两组均予低流量吸氧、止咳化痰、多索茶碱解痉平喘、适当抗感染等治疗。实验组在此基础上,同时吸入噻托溴铵吸入剂,1吸/次,1次/d,疗程均为6周。观察吸入前后临床症状变化、肺功能变化。结果 COPD患者经噻托溴铵吸入治疗,症状及肺功能均明显改善,实验组与对照组差异有统计学意义(χ2=61495,P<0.05),其总有效率(86.6%)明显高于对照组(73.3%)。不良反应:实验组除6例口干、1例便秘,无其他不良反应。结论吸入噻托溴铵干粉治疗COPD合并呼吸衰竭疗效显著,具有临床应用价值。
Objective To investigate the clinical efficacy of tiotropium bromide in the treatment of chronic obstructive pulmonary disease (COPD) with respiratory failure. Methods 120 patients diagnosed as COPD were randomly divided into experimental group and control group, 60 cases in each group. Both groups were given low-flow oxygen, cough and phlegm, Doxofylline antispasmodic and anti-asthma, appropriate anti-infection treatment. The experimental group on this basis, while inhaled tiotropium bromide, 1 suction / time, 1 / d, treatment for 6 weeks. Observed before and after inhalation changes in clinical symptoms, lung function changes. Results The patients with COPD were treated with tiotropium bromide, and the symptoms and lung function were significantly improved. The difference between the experimental group and the control group was statistically significant (χ2 = 61495, P <0.05), and the total effective rate was 86.6% Control group (73.3%). Adverse reactions: Except for 6 cases of dry mouth in the experimental group, 1 case of constipation, no other adverse reactions. Conclusion The efficacy of inhaled tiotropium bromide in treating COPD with respiratory failure is significant and has clinical value.